2076975 2077203
최종편집 2024-06-24 07:03 (월)
Daiichi Sankyo claims top spot among Japanese pharmaceutical offshoots in Korea
상태바
Daiichi Sankyo claims top spot among Japanese pharmaceutical offshoots in Korea
  • Jaehoon SongㆍHyeokgi Lee, Newsmp
  • 승인 2023.07.13 19:44
  • 댓글 0
이 기사를 공유합니다

Daiichi Sankyo’s sales of KRW 253.2 billion lead ahead of Takeda with KRW 249.6 billion
Astellas and Otsuka follow with KRW 232.2 billion and KRW 221.7 billion

[Newsmp] Daiichi Sankyo Korea surpassed KRW 250 billion in annual sales last year, securing the top position in revenue among Japanese pharmaceutical companies operating in Korea.

The audit reports showed that Daiichi Sankyo achieved sales of KRW 253.2 billion last year, recording a growth of 3.2% compared to the previous year and becoming the only one among nine Japanese subsidiaries to surpass KRW 250 billion.

Takeda Korea could not surpass Daiichi Sankyo despite a 7.8% growth to KRW 249.6 billion, which was nearing the RW 250 billion mark.

Astellas Pharma Korea, which was in the lead ahead of Daiichi Sankyo by a narrow margin in 2021, recorded a decline of 5.8% in sales, ending at KRW 232.2 billion.

Following behind, Otsuka Korea experienced a 7.3% growth, reaching revenue of KRW 221.7 billion, and four leading companies achieved sales of over KRW 200 billion.

In contrast, Eisai Korea saw its sales drop to KRW 140.5 billion, showing a decline of 34.0% last year, despite achieving sales of KRW 212.9 billion in 2021.

Santen Korea and Kyowa Kirin Korea achieved growth rates of 10.4% and 16.3%, generating sales of KRW 120.2 billion and KRW 92.4 billion.

Moreover, Mitsubishi Tanabe Pharma recorded sales of nearly KRW 69.7 billion, almost identical to 2021, while Ono Pharma Korea expanded its sales to nearly KRW 10 billion, rising from KRW 40.7 billion to KRW 50.1 billion.

Even though the sales scale of six out of the nine companies expanded, the total sales volume decreased by 0.8% from KRW 1.4418 trillion to KRW 1.4295 trillion, mainly due to the notable decline in Eisai's sales.

In the meantime, the operating profit showed a weaker performance, as the combined operating profit witnessed a significant decline of 17.7% from KRW 143.2 billion to KRW 117.9 billion.

In particular, Eisai's operating profit, which suffered a significant decrease in sales, plummeted by 77.3% from KRW 22.8 billion to KRW 5.2 billion, while Daiichi Sankyo, the sales leader, also saw a 15.7% decrease in operating profit from 26.2 billion to 22.1 billion.

Otsuka Korea, the only Japanese pharmaceutical company achieving operating profit in the KRW 300 billion mark, also saw a notable decline of 17.7%, decreasing from KRW 38.6 billion in 2021 to KRW 31.8 billion in the past year.

Despite achieving double-digit sales growth, Kyowa Kirin Korea faced a more than 10% reduction in operating profit, which fell from KRW 6.7 billion to KRW 5.9 billion.

On the other hand, regardless of a decline in revenue, Astellas Pharma increased its operating profit from KRW 15.2 billion to KRW 17.6 billion, while Santen, which recorded double-digit sales growth, also marked a 6.4% growth in operating profit from KRW 15.9 billion to KRW 16.9 billion.

Furthermore, Mitsubishi Tanabe Pharma saw a 6.7% growth in operating profit, increasing from KRW 6.8 billion to KRW 7.3 billion, while Ono Pharma Korea generated an expansion of 21.0% in operating profit, rising from KRW 3 billion to KRW 3.6 billion.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.